Overview

Pharmacokinetics and Safety/Tolerability Profile of CKD-379

Status:
Recruiting
Trial end date:
2022-09-05
Target enrollment:
Participant gender:
Summary
A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical